Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. has reported a substantial growth for the first half of 2024, with a 190% increase in hospital adoption of their Steriwave technology and a 101% rise in revenue. The company has also entered a strategic partnership with Mölnlycke Health Care to expand into European and Middle Eastern markets, and is advancing towards critical care applications, aiming for further expansion and a US market breakthrough.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
